Cell transplant for heart failure
Pr. Menasché, of the Saint-Louis Hospital (Paris), is a name that will remain in the annals of modern medicine. He and his team were the first to have a cell transplant for heart failure. This is a technique of cell therapy. Heart cells do not have any regenerative capacity. The idea is to take muscle cells elsewhere and re-implant them in the heart. There is no risk of rejection. Muscle stem cells were taken from a patient’s thigh: the myoblasts which were then cultured to almost a billion in a few weeks. Then they were implanted in the heart of the patient: the part of the damaged heart resumes to work partially.
We also quote the “smart stent” invented by Franz Bozsak. He discovered that the two main complications of the pose are restenosis (vascular cells colonize the implant and gradually close the artery) and thrombosis, due to the formation of a blood clot inside the stent and resulting in one death in half of the cases. “Two phenomena related to implantation, clarifies Franz Bozsak. During the installation, the endothelial cells lining the artery wall are damaged so that they lose their anticoagulant function or else the smooth muscle cells located just below migrate on the stent, “he clarifies. And so the goal of this new device? Develop a stent capable of providing information on the stage of healing of the artery in order to know when to stop treatment. How? By equipping this small metal spring sensors capable of distinguishing endothelial cells, smooth muscle cells and blood clots.
And always among the development of stents, there is also one that is biodegradable; device developed and developed by Professor Antoine Lafont. In collaboration with the chemist and specialist biodegradable polymers, Professor Michel Vert, the device is fully guaranteed to degrade gradually a few months after its installation, on average three months. Moreover, this delay should be able to allow the artery to regain its initial tone as well as its original configuration. The advantage of this new stent compared to other models that were already biodegradable, lies in its time of biodegradation, which is much faster, if the other models generally take two years. And thanks to this new focus on the degradation time, patients will have the advantage of reducing the time taken for antiplatelet drugs.
Finally, we do not forget the cardiologist surgeon Philippe Bonhoeffer, to whom we owe the melody valve. The valve is catheterized instead of open-heart surgery in patients with congenital heart disease affecting the function of their pulmonary valve. It is indeed a viable procedural alternative, designed to reduce the number of invasive surgeries and their associated risks. In addition, it represents an exciting capital breakthrough for people who require multiple open heart surgeries in their lifetime. Let us note each year, some 34,000 children are born in the United States with a congenital heart disease. The use of the melody valve is an important revolution for these patients who will require an intervention of the heart from the youngest age.